Introduction
============

Acute Lung Injury (ALI) and acute respiratory distress syndrome (ARDS) are two types of common and complex inflammatory lung diseases ([@b1-etm-0-0-6692]). As a kind of novel gene regulatory molecule, microRNAs play an important role in various complicated diseases, including ALI ([@b2-etm-0-0-6692]).

ARDS is a common and major inflammatory lung disease, characterized by rapid progression. It is estimated that there are 190,000 newly diagnosed cases of ALI in the United States alone each year, 75,000 of whom die annually ([@b3-etm-0-0-6692]). In China, the incidence of ALI/ARDS is higher, with mortality rate as high as 52% ([@b2-etm-0-0-6692]). In recent years, it has been noted that miRNAs play an important role in multiple biological processes and signal transduction pathways of ALI/ARDS ([@b4-etm-0-0-6692]).

The expression changes of miRNAs are associated with immune response, inflammatory signaling pathways and pathogenesis of inflammatory lung diseases, including ALI, hence, miRNAs can be considered as new therapeutic target ([@b4-etm-0-0-6692]). Although miRNAs change the expression of related genes moderately, it may greatly affect the expression of a large number of downstream genes, thereby influencing a variety of biological processes. Therefore, miRNAs might be potentially used as one of the markers ([@b5-etm-0-0-6692],[@b6-etm-0-0-6692]).

Toll-like receptor (TLR) family serves both as signal molecules and receptors of lipopolysaccharide (LPS) ([@b7-etm-0-0-6692]). TLR4, a member of TLR family, is mainly distributed on the surface of mononuclear macrophage, which mediates the intracellular conduction of LPS inflammation signals, and is the preferential receptor of LPS ([@b8-etm-0-0-6692]). Nuclear factor (NF)-κB collectively refers to many DNA binding proteins which specifically bind to κB site of promoters of a variety of genes, and promotes transcription, which plays an important role in immune response, inflammatory response and cell growth regulation ([@b7-etm-0-0-6692]). NF-κB signal pathway is the most important downstream pathway among all signal transduction pathways mediated by LPS, suggesting that TLR4/NF-κB pathway may be the key target to trigger inflammatory response and organ injury ([@b9-etm-0-0-6692]). Zhang and Xu ([@b10-etm-0-0-6692]) has indicated that miRNA-140-5p regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation. Herein, the aim of the present study was to investigate the function of miRNA-140-5p in ts ALI and its regulatory mechanism.

Materials and methods
=====================

### Animals and ethics statement

C57/BL6 mice, 6--8 weeks of age, were purchased from Guangdong Medical Laboratory Animal Centre (Guangzhou, China). The mice were randomly divided into two groups, control group (n=6) and Model group (n=8). In Model group, mice were inhaled with 1,000 µg/ml LPS for 1 h at 3 h intervals over a period of 8 h. In control group, mice were inhaled with normal saline for 1 h at 3 h intervals over a period of 8 h. The experimental procedures conformed to the Guide for the Care and Use of Laboratory Animal, and all of the procedures were approved by the Institutional Ethics Committee of Sichuan Cancer Hospital (Sichuan, China).

### Enzyme-linked immunosorbent assay (ELISA) kits

Lung tissue or transfection cells were extracted in lysis buffer (Beyotime Institute of Biotechnology, Nanjing, China) and Protein concentration was measured by the Pierce™ BCA protein assay kit Beyotime Institute of Biotechnology, Nanjing, China). 10 µg extracts was used to analyze tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and MPO levels using ELISA kits.

### Histopathology

Lung tissue samples were fixed in 4% paraformaldehyde for 24 h, embedded in paraffin, and cut into 5-µm thick sections. Lung tissue samples was stained with hematoxylin and eosin assay for 5 min and observed using a phase fluorescence microscope (Axio Observer; Carl Zeiss AG, Oberkochen, Germany).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA from serum was extracted using TRIzol (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocol. cDNA was reverse transcribed, which was performed as described using the PrimeScript™ RT reagent kit (Takara Bio, Inc., Otsu, Japan). Relative gene expression was quantified using ABI 7900HT Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) with SYBR^®^ Premix Ex Taq™ II kit (Takara Bio, Inc.). The thermocycling conditions were as follows: 94°C for 10 min, followed by 40 cycles of 94°C for 15 sec, 55°C for 30 sec and 72°C for 30 sec. The relative expression levels were analyzed using the 2^−ΔΔCq^ method ([@b11-etm-0-0-6692]).

### Cell culture and treatment

Human lung A549 cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal calf serum (FCS; Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.) at 5% CO~2~ at 37°C.

### Transfection

miRNA-140-5p mimic and mimic control (mimic-NC) were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). A549 cell was co-transfected with 20 nM miRNA-140-5p mimic and mimic control (mimic-NC) using Lipofectamine 3000 (Invitrogen, Guangzhou, China). After transfection for 4 h, old medium was removed and new medium was added into cell. After transfection for 48 h, A549 cell was treated by 100 ng/ml of LPS for 4 h, and then analyzed other study.

### Dual luciferase assays

293 cells were cotransfected with TLR4 luciferase reporter construct with miR-140-5p using Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, Inc.) for 48 h. Luciferase activity was assayed using a Dual-Luciferase Reporter Assay System (Promega Corporation, Madison, WI, USA).

### Western blotting

Transfection cells were extracted in lysis buffer (Beyotime Institute of Biotechnology, Nanjing, China) and Protein concentration was measured by the Pierce™ BCA protein assay kit (Beyotime Institute of Biotechnology, Nanjing, China). Equal amount of the extracts (50 µg) were loaded and separated in a 8--10% polyacrylamide gel, then proteins were transferred onto a PVDF membrane (EMD Millipore, Billerica, MA, USA). Membranes were incubated with TLR4, myeloid differentiation primary response 88 (MyD88), NF-κB, and GADPH (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 4°C over-night. Membranes were incubated with goat anti-rabbit HRP (Santa Cruz Biotechnology, Inc.; 1:2,000 dilution).

### Immunofluorescence

Cell was washed with PBS and fixed with 4% paraformaldehyde for 15 min, and blocked with 0.5 ml PBS containing 0.1% Triton X-100 and 1% BSA at room temperature for 1 h. Cell were incubated with TLR4 (Santa Cruz Biotechnology, Inc.) at 4°C over-night. Cell were then washed with PBS and incubated with Alexa 555 labelled Rabbit Anti-Goat secondary antibody (Santa Cruz Biotechnology, Inc.) in the dark for 1 h at room temperature and stained with DAPI for 15 min in the dark. Images cells were obtained by using a phase fluorescence microscope (Axio Observer; Carl Zeiss AG).

### Statistical analysis

All data are expressed as the mean ± standard deviation. Data were analyzed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Independent-samples t-tests between two groups and one-way analysis of variance for multiple comparisons with Dunnett\'s post hoc test were performed. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### miR-140-5p expression in mice with ALI

The expression of miR-140-5p was examined in ALI and control mice. Firstly, HE staining showed there was diffuse alveolar damage in ALI group, compared with control group ([Fig. 1A](#f1-etm-0-0-6692){ref-type="fig"}). Then, the levels of TNF-α, IL-1β, IL-6 and MPO were increased in ALI group in comparison to control group ([Fig. 1B-E](#f1-etm-0-0-6692){ref-type="fig"}). As shown in [Fig. 1G](#f1-etm-0-0-6692){ref-type="fig"}, miR-140-5p expression in mice with ALI was suppressed, compared with normal control group. Therefore, miR-140-5p may be a key factor for ALI.

### miR-140-5p regulated inflammation in in vitro model of ALI

To explore whether miR-140-5p regulated inflammation of ALI, the levels of TNF-α, IL-1β, IL-6 and MPO were measured in this study. As shown in [Fig. 2A and B](#f2-etm-0-0-6692){ref-type="fig"}, anti-miR-140-5p mimics or miR-140-5p mimics inhibited or increased the expression of miR-140-5p in *in vitro* model of ALI, compared with that in the control group. The levels of TNF-α, IL-1β, IL-6 and MPO were significantly elevated in *in vitro* model of ALI following miR-140-5p down-regulation, compared with control group ([Fig. 2C-F](#f2-etm-0-0-6692){ref-type="fig"}). Over-expression of miR-140-5p inhibited the levels of TNF-α, IL-1β, IL-6 and MPO in *in vitro* model of ALI, in comparison with control group ([Fig. 2G-J](#f2-etm-0-0-6692){ref-type="fig"}). Hence, miR-140-5p may regulate the inflammation of ALI.

### miR-140-5p regulated inflammation in in vitro model of ALI by MyD88/NF-KB signaling pathway by targeting TLR4

Next TLR4/MyD88/NF-κB signaling pathway was measured in this study to determine the mechanism function of miR-140-5p in ALI. As shown in [Fig. 3A and B](#f3-etm-0-0-6692){ref-type="fig"}, putative binding sequences of miR-140-5p in the 3′UTR of TLR4, and the luciferase assay of miR-140-5p was reduced in WT group, compared with that in the control group. Immunofluorescence showed that over-expression of miR-140-5p suppressed TLR4 protein expression in *in vitro* model of ALI, compared with control group ([Fig. 3C](#f3-etm-0-0-6692){ref-type="fig"}). Down-regulation of miR-140-5p induced TLR4/MyD88/NF-κB signaling pathway in *in vitro* model of ALI, in comparison to control group ([Fig. 4A-D](#f4-etm-0-0-6692){ref-type="fig"}). Over-expression of miR-140-5p suppressed TLR4/MyD88/NF-κB signaling pathway in *in vitro* model of ALI, compared with control group ([Fig. 4E-H](#f4-etm-0-0-6692){ref-type="fig"}). Hence, miR-140-5p may reduce the inflammation of ALI by regulating TLR4/MyD88/NF-κB signaling pathway *in vitro*.

### The inhibition of TLR4 suppressed the effects of TLR4/MyD88/NF-κB signaling pathway on anti-miR-140-5p in ALI in vitro

To confirm the mechanism function of TLR4 in miR-140-5p in ALI *in vitro*, TLR4 inhibitor (TAK-242, 0.5 nM, 48 h) was used to inhibit the expression of TLR4. As shown in [Fig. 5A-D](#f5-etm-0-0-6692){ref-type="fig"}, TLR4 inhibitor suppressed TLR4/MyD88/NF-κB signaling pathway in *in vitro* model of ALI following miR-140-5p down-regulation, compared with miR-140-5p down-regulation group. In addition, TLR4 inhibitor also reduced the levels of TNF-α, IL-1β, IL-6 and MPO in *in vitro* model of ALI following miR-140-5p down-regulation, compared with miR-140-5p down-regulation group ([Fig. 5E-H](#f5-etm-0-0-6692){ref-type="fig"}).

### The inhibition of NF-κB suppressed the effects of NF-κB signaling pathway on anti-miR-140-5p in ALI in vitro

Meanwhile, NF-κB inhibitor (JSH-23, 2 µM, 48 h) was utilized to suppress the protein expression of NF-κB in ALI *in vitro* following miR-140-5p down-regulation, compared with miR-140-5p down-regulation group ([Fig. 6A and B](#f6-etm-0-0-6692){ref-type="fig"}). NF-κB inhibitor also inhibited the levels of TNF-α, IL-1β, IL-6 and MPO in ALI *in vitro* following miR-140-5p down-regulation, in comparison with miR-140-5p down-regulation group ([Fig. 6C-F](#f6-etm-0-0-6692){ref-type="fig"}).

Discussion
==========

ALI and ARDS are acute respiratory distress syndromes caused by pulmonary capillary diffuse injury and enhanced permeability due to internal and external factors, mainly characterized by pulmonary edema, hyalinosis and atelectasis, with respiratory distress and refractory hypoxemia as clinical features ([@b3-etm-0-0-6692]). Internal pulmonary factors include direct injury to the lung, such as injury by stomach contents, lung injury, radiation injury, severe pneumonia, etc. External pulmonary factors consist of severe shock, endotoxemia, severe non-thoracic trauma, large area burns, large blood transfusion, acute pancreatitis and drug poisoning ([@b12-etm-0-0-6692]). In spite of recent great progress concerning the studies on ALI/ARDS, there is still a lack of effective clinical treatments in addition to protective mechanical ventilation ([@b13-etm-0-0-6692]). Therefore, it is urgent to explore a novel therapeutic strategy to alleviate ALI/ARDS ([@b13-etm-0-0-6692]). To the best of our knowledge, this is the first report demonstrating the suppressive expression of miR-140-5p in mice with ALI, compared with normal control group. Nagy *et al* ([@b14-etm-0-0-6692]) has showed that miR-140-5p regulates inflammation in cystic fibrosis.

At present, researches concerning the relationship between ALI/ARDS and miRNAs are still in early stage, and the study on human lung tissues and organs will provide direct and reliable evidence about the role of miRNA in ALI/ARDS ([@b5-etm-0-0-6692]). Our study showed that down-regulation of miR-140-5p significantly induced the levels of TNF-α, IL-1β, IL-6 and MPO in ALI *in vitro*. Li *et al* ([@b15-etm-0-0-6692]) reported that miR-140-5p inhibited inflammatory cytokines secretion through targeting TLR4.

ALI, a kind of severe lung infectious disease, is mainly caused by bacterial infection-induced sepsis. LPS, the main component of the cell wall of gram negative bacteria, is the major pathogenic factor of ALI ([@b9-etm-0-0-6692]). LPS interacts with the receptor on the effector cell membrane to initiate an intracellular signal transduction system, which causes the activation of nuclear transcription factor NF-κB, to initiate gene transcription and to produce a variety of proinflammatory cytokines. TLR4 is considered to be an important receptor mediating LPS signal transduction ([@b16-etm-0-0-6692]). MyD88, a key adaptor molecule in TLR4 signaling pathway, plays an important role in the transmission of upstream signaling as well as the incidence and progression of diseases ([@b17-etm-0-0-6692]). TLR4-mediated MyD88 signal pathway regulates the expression of multiple genes related to inflammation during immune response to pathogen invasion ([@b18-etm-0-0-6692]). Consistent with this finding, our studies showed that over-expression of miR-140-5p significantly suppressed TLR4/MyD88/NF-κB signaling pathway in *in vitro* model of ALI. Sun *et al* ([@b19-etm-0-0-6692]) suggest that miR-140-5p mediated the inflammation of human dental pulp stem cells through TLR4 signaling pathway.

NF-κB, one of the downstream molecules of TLR4, is a heterodimer composed of p65 and p50 subunits ([@b20-etm-0-0-6692]). In the inactive state, NF-κB binds to inhibitive protein IκB and exists in the cytoplasm in an inactive form ([@b21-etm-0-0-6692]). Some studies have showed that in microglia, LPS activates TLR4, releases the inhibition of NF-κB by IκB, promotes NF-κB nuclear translocation, and stimulates the expression of genes related to inflammation, thereby promoting the synthesis and release of IL-1 and TNF-α ([@b21-etm-0-0-6692],[@b22-etm-0-0-6692]). We found that the inhibition of TLR4 using TLR4 inhibitor or NF-κB inhibitor reduced the proinflammation of miR-140-5p in ALI *in vitro* through TLR4/MyD88/ NF-κB signaling pathway. Jude *et al* ([@b23-etm-0-0-6692]) indicated that miR-140-3p regulated TNF-α-induced CD38 expression in human airway smooth muscle cells through regulating the protein expression of p38 MAPK and NF-κB.

Results from our current study suggest that miR-140-5p inhibits the inflammation of ALI via TLR4/MyD88/ NF-κB signaling pathway. Our findings may provide a novel strategy of miR-140-5p for the treatment of ALI and protection against inflammation in further clinical research.
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![miR-140-5p expression in mice with ALI. (A) Hematoxylin and eosin staining (scale bars, 100 µm). (B) TNF-α, (C) IL-1β, (D) IL-6 and (E) MPO protein levels. (F) The miR-140-5p expression gene chip and (G) the results of reverse transcription-quantitative polymerase chain reaction. \*\*P\<0.01 vs. control group. ALI, acute lung injury; miR, microRNA; TNF-α, tumor necrosis factor-α; IL, interleukin; MPO, myeloperoxidase.](etm-16-05-3913-g00){#f1-etm-0-0-6692}

![miR-140-5p regulates inflammation in an *in vitro* model of acute lung injury. Reverse transcription-quantitative polymerase chain reaction was performed to determine the expression of (A and B) miR-140-5p in the anti-140-5p and miR-140-5p groups, as well as that of (C) TNF-α, (D) IL-1β, (E) IL-6 and (F) MPO levels following of miR-140-5p downregulation; and also (G) TNF-α, (H) IL-1β, (I) IL-6 and (J) MPO levels following miR-140-5p overexpression. \*\*P\<0.01 vs. negative control group. miR, microRNA; Anti-140-5p, downregulation of miR-140-5p group; miR-140-5p, overexpression of miR-140-5p group; TNF-α, tumor necrosis factor-α; IL, interleukin; MPO, myeloperoxidase.](etm-16-05-3913-g01){#f2-etm-0-0-6692}

![miR-140-5p regulates TLR4 in the *in vitro* acute lung injury model. (A) Putative binding sequences of miR-140-5p in the 3′-untranslated region of TLR4 and (B) the luciferase assay. (C) Immunofluorescence for TLR4 protein expression (magnification, ×100). \*\*P\<0.01 vs. negative control group. miR, microRNA; miR-140-5p, overexpression of miR-140-5p group; MUT, mutant; WT, wild type; TLR4, Toll-like receptor 4.](etm-16-05-3913-g02){#f3-etm-0-0-6692}

![miR-140-5p regulates inflammation in the *in vitro* acute lung injury model through the MyD88/NF-KB signaling pathway by targeting TLR4. (A) TLR4, (B) MyD88 and (C) NF-κB protein expression was statistically analyzed. (D) Western blotting assays for the (E) TLR4, (F) MyD88 and (G) NF-κB signaling pathway were performed following miR-140-5p downregulation, as well as following (H) the overexpression of miR-140-5p. \*\*P\<0.01 vs. negative control group. miR, microRNA; Anti-140-5p, downregulation of miR-140-5p group; miR-140-5p, over-expression of miR-140-5p; TLR4, Toll-like receptor 4; MyD88, myeloid differentiation primary response 88; NF-κB, nuclear factor-κB.](etm-16-05-3913-g03){#f4-etm-0-0-6692}

![Inhibition of TLR4 suppresses the TLR4/MyD88/NF-κB signaling pathway and the effects of anti-miR-140-5p on the *in vitro* acute lung injury model. The protein expression of (A) TLR4, (B) MyD88 and (C) NF-κB was determined by (D) western blotting assays. The protein expression of (E) TNF-α, (F) IL-1β, (G) IL-6 and (H) MPO was also evaluated. \*\*P\<0.01 vs. negative control group; ^\#\#^P\<0.01 vs. anti-140-5p group. miR, microRNA; Anti-140-5p, downregulation of miR-140-5p group; TLR4 i, downregulation of miR-140-5p and TLR4 inhibitor group; TLR4, Toll-like receptor 4; MyD88, myeloid differentiation primary response 88; NF-κB, nuclear factor-κB; TNF-α, tumor necrosis factor-α; IL, interleukin; MPO, myeloperoxidase.](etm-16-05-3913-g04){#f5-etm-0-0-6692}

![Inhibition of NF-κB suppresses the NF-κB signaling pathway and the effects of anti-miR-140-5p on the *in vitro* acute lung injury model. (A) NF-κB protein expression was determined by (B) western blot assays, as well as (C) TNF-α, (D) IL-1β, (E) IL-6 and (F) MPO levels. \*\*P\<0.01 vs. negative control group; ^\#\#^P\<0.01 vs. anti-140-5p group. miR, microRNA; NF-κB, nuclear factor-κB; Anti-140-5p, downregulation of miR-140-5p group; NF-κB i, downregulation of miR-140-5p and NF-κB inhibitor group; TNF-α, tumor necrosis factor-α; IL, interleukin; MPO, myeloperoxidase.](etm-16-05-3913-g05){#f6-etm-0-0-6692}
